Biogen, Inc. (NASDAQ/BGEN) today announced that Bob Hamm has been appointed Senior Vice President of North American Commercial Operations. In this newly created position, Mr. Hamm will oversee Biogen’s U.S. Neurology Business Unit, U.S. Dermatology Business Unit, U.S. Commercial Services, and Canadian Operations.
Mr. Hamm, who will report to Hans Peter Hasler, Executive Vice President, Commercial Operations, will commence his new duties effective January 1, 2003.
“We are very pleased to have Bob Hamm lead our North American Commercial Operations,” said Mr. Hasler. “As Biogen transitions to a multi-product biotechnology company, Bob’s industry experience, strategic thinking, and leadership abilities will play a critical role in growing our business.”
Mr. Hamm joined Biogen in 1994 as Associate Director, Logistics. In that position, he established Biogen’s supply chain and played a major role in the company’s transformation from a research organization to an operating company in 1996. Following an assignment in Europe from 1996 to 1999, Mr. Hamm was named Vice President of Manufacturing and Engineering for Biogen. In 2001, he was appointed head of Sales and Marketing of North America. In 2002, Mr. Hamm was appointed Senior Vice President for Europe, Canada, and the Middle East.
Biogen, Inc., winner of the U.S. National Medal of Technology, is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from U.S. and worldwide sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at http://www.Biogen.com
Director, Public Affairs
Tel: (617) 914-6524
Investment Community Contact:
Manager, Investor Relations
Tel: (617) 679-2812